Evidence map›Paper›PMID 35784732›Full record

ArticleFrontiers in pharmacology2022

Berberine Suppresses Lung Metastasis of Cancer

Wenjia Tian, Huifeng Hao, Ming Chu, Jingjing Gong, Wenzhe Li, Yuan Fang, Jindong Zhang, Cunzheng Zhang, Yonghui Huang, Fei Pei and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Advance in identified targets of berberine.Frontiers in pharmacology · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Wenjia TianDepartment of Gastroenterology, Peking University Third Hospital, Beijing, China.
Huifeng HaoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education Beijing), Department of Integration of Chinese and Western Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Ming ChuDepartment of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
Jingjing GongInstitute of Systems Biomedicine, Peking University Health Science Center, Beijing, China.
Wenzhe LiState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China.
Yuan FangDepartment of Gastroenterology, Peking University Third Hospital, Beijing, China.
Jindong ZhangDepartment of Gastroenterology, Peking University Third Hospital, Beijing, China.
Cunzheng ZhangDepartment of Gastroenterology, Peking University Third Hospital, Beijing, China.
Yonghui HuangDepartment of Gastroenterology, Peking University Third Hospital, Beijing, China.
Fei PeiDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Liping DuanDepartment of Gastroenterology, Peking University Third Hospital, Beijing, China.
Peking University · CNPeking University Third Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the effects of berberine (BBR) on pancreatic cancer (PC) lung metastasis and explored the underlying mechanisms, using a BALB/C-nu/nu nude mouse model injected with PC cells (AsPC-1). Intragastric administration of BBR dose-dependently improves survival of mice intravenously injected with AsPC-1 cells, and reduces lung metastasis. Especially, BBR significantly reduces lung infiltration of circulating tumor cells (CTCs) 24 h after AsPC-1 cells injection.

Indexed as

berberinecancer cellendothelial barrierendothelial cellmetastasispancreatic cancerTGFBR1trans-endothelial migration

Identifiers

PMID35784732
PMCPMC9243563
OpenAlexW4283019722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.